For patients with advanced pancreatic cancer, the low-risk subgroup showed significantly higher IPS scores when treated with CTLA4 blockers alone or a combination of CTLA4 and PD1 blockers, compared to the high-risk group. Here, CTLA4 is linked to familial pancreatic carcinoma.